Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 113
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
Identification of novel therapeutic approaches to selectively target senescent cells in prostate cancer In corso di stampa Bressan SilviaZumerle SaraMontopoli MonicaAlimonti Andrea + - - Identification of novel therapeutic approaches to selectively target senescent cells in prostate cancer.
Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells 2024 Bressan, SilviaGianfanti, FedericoDesbats, Maria AndreaContu, LilianaMaraccani, LuisaMontopoli, MonicaAlimonti, Andrea + CANCER CELL - -
The potential role of the microbiota in prostate cancer pathogenesis and treatment 2023 Maraccani, LAlimonti, A + NATURE REVIEWS. UROLOGY - -
VSSP-activated macrophages mediate senescence and tumor inhibition in a preclinical model of advanced prostate cancer 2023 Alimonti, Andrea + CELL COMMUNICATION AND SIGNALING - -
Esmethadone-HCl (REL-1017): a promising rapid antidepressant 2023 De Martin, SaraMattarei, AndreaComai, StefanoAlimonti, AndreaFurlan, Alberto + EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE - -
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer 2023 Montopoli, MonicaAlimonti, Andrea + CANCER CELL - -
Genetic ablation of ketohexokinase C isoform impairs pancreatic cancer development 2023 Alimonti, Andrea + ISCIENCE - -
CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression 2023 Alimonti, Andrea + SCIENTIFIC REPORTS - -
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells 2023 Fassan, MatteoAlimonti, Andrea + NATURE CANCER - -
Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer 2022 Alimonti A. + NATURE COMMUNICATIONS - -
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer 2022 Bianca Calı`Andrea AlimontiSilvia Bressan + EUROPEAN UROLOGY - -
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors 2022 De Martin, SaraMattarei, AndreaAlimonti, Andrea + PHARMACEUTICALS - -
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling 2022 De Martin, SaraMattarei, AndreaAlimonti, Andrea + INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES - -
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial 2022 De Martin S.Alimonti A.Mattarei A. + THE AMERICAN JOURNAL OF PSYCHIATRY - -
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis 2021 Minini, MirkoMosole, SimoneAlimonti, Andrea + SCIENCE - -
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis 2021 Alimonti A. + CANCER CELL - -
CD38 in Advanced Prostate Cancers 2021 Alimonti, Andrea + EUROPEAN UROLOGY - -
Identification of novel therapeutic approaches to selectively target senescent cells in prostate cancer 2021 Zumerle SaraMontopoli MonicaAlimonti Andrea + - - Pharmadvance
A multidisciplinary approach for the identification and validation of novel prostate cancer targets - ABSTRACTS OF THE 40TH CONGRESS OF THE ITALIAN PHARMACOLOGICAL SOCIETY (SIF) 2021 Federico GianfantiAndrea AlimontiMonica Montopoli + PHARMADVANCES - -
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer 2021 Alimonti, Andrea + CANCER RESEARCH - -
Mostrati risultati da 1 a 20 di 113
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile